Company intelligence / Profile preview

Woodward

Wixom, Michigan, United States

Ownership: Public · WWD
Development stage: Other

Overview

Woodward Pharma Services commercializes branded and generic prescription drugs in the U.S., including LOVAZA (approved for hypertriglyceridemia) and LUNESTA (eszopiclone, indicated for insomnia); previous assets included rosiglitazone maleate (formerly used in diabetes, now withdrawn in the U.S.).

Therapeutic areas: Metabolic DisordersPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

GlaxoSmithKline (GSK): asset acquisition (LOVAZA)Sumitomo Pharma/Sunovion: asset acquisition (LUNESTA)

Financials

Market cap: $20.1B
Total revenue: $1.1B
Enterprise value: $21B

Beyond the preview

Go deeper on Woodward.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Woodward.

Explore the full profile